Chris Evald
About Chris Evald
Chris Evald is a Finance Business Partner at Dechra Pharmaceuticals Plc, with over a decade of experience in financial management. He holds multiple degrees from Aarhus Bss - Aarhus University and has worked in both Denmark and the United Kingdom.
Work at Dechra Pharmaceuticals
Chris Evald has been employed at Dechra Pharmaceuticals Plc since 2014, serving as a Finance Business Partner. In this role, he contributes to the company's financial strategies and operations, leveraging his extensive background in finance and business administration. Prior to his current position, he worked as a Business Controller at the same company from 2010 to 2014. His tenure at Dechra Pharmaceuticals spans over a decade, highlighting his commitment and expertise within the organization.
Education and Expertise
Chris Evald holds multiple degrees from Aarhus Bss - Aarhus University. He achieved a Bachelor of Science in Business Administration and Business Law from 2000 to 2003. Following this, he completed a Master of Science in Accounting from 2003 to 2005. His educational journey culminated with another Master of Science in Business Administration and Law from 2006 to 2008. This strong academic foundation supports his comprehensive approach to financial management.
Background
Chris Evald has a diverse background in finance, having worked in both Denmark and the United Kingdom. He began his career at Cheminova A/S as a Financial Controller from 2005 to 2009, where he gained valuable experience in financial oversight. His transition to Dechra Pharmaceuticals in 2010 marked a significant step in his career, allowing him to expand his expertise and responsibilities in financial management.
Achievements
Throughout his career, Chris Evald has demonstrated a progression in responsibilities, transitioning from a Business Controller to a Finance Business Partner at Dechra Pharmaceuticals. This shift indicates his growing expertise and the trust placed in him by the organization. His contributions have been integral to the financial strategies and operations of Dechra Pharmaceuticals, reflecting his commitment to the company's success.